Navigation Links
Analysis supports use of risk equations to guide statin therapy
Date:3/29/2014

In an analysis of almost 11,000 patients, an assessment of equations that help guide whether a patient should begin taking a statin (cholesterol lowering medication) found that observed and predicted 5-year atherosclerotic cardiovascular disease risks were similar, suggesting that these equations are helpful for clinical decision making, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions.

The American College of Cardiology (ACC) and the American Heart Association (AHA) recently published the 2013 Guideline on the Assessment of Cardiovascular Risk. As part of this guideline, a group of experts developed the Pooled Cohort risk equations, which were designed to estimate 10-year risk for nonfatal myocardial infarction (MI; heart attack), coronary heart disease (CHD) death, and nonfatal or fatal stroke, according to background information in the article.

Paul Muntner, Ph.D., of the University of Alabama at Birmingham, and colleagues examined the Pooled Cohort risk equations in adults (age 45 to 79 years) enrolled in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study between January 2003 and October 2007, and followed up through December 2010. The researchers studied participants for whom atherosclerotic CVD risk may trigger a discussion of statin initiation (patients without clinical atherosclerotic CVD or diabetes, low-density lipoprotein cholesterol level between 70 and 189 mg/dL, and not taking statins; n = 10,997). Additional analyses, limited to Medicare beneficiaries (n = 3,333), added atherosclerotic CVD events identified in Medicare claims data.

Among the study population (n=10,997) for whom statin treatment should be considered based on atherosclerotic CVD risk there were 338 events (192 CHD events, 146 strokes). The researchers found that the observed and predicted 5-year atherosclerotic CVD incidence rates were similar.

There were 234 atherosclerotic CVD events (120 CHD events, 114 strokes) among the subset of Medicare beneficiaries and the observed and predicted 5-year atherosclerotic CVD incidence rates were also similar for the various risk categories in this population.

"These findings support the validity of the Pooled Cohort risk equations to inform clinical management decisions," the authors write. "Because the Pooled Cohort risk equations were designed to estimate 10-year atherosclerotic cardiovascular disease risk, studies are needed to ensure its accurate calibration over a longer duration."


'/>"/>

Contact: Nicole Wyatt
nwyatt@uab.edu
205-934-8938
The JAMA Network Journals
Source:Eurekalert

Related medicine news :

1. Analysis: 32 years of US filicide arrests
2. Whole genome analysis, stat
3. Analysis of calls to IBD clinic predicts emergency visits and hospitalizations, Pitt finds
4. New analysis finds hempseed oil packed with health-promoting compounds
5. Global In Vitro Diagnostics (IVD) Market 2013
6. Industry Analysis, Size, Share, Growth, Trends and Forecast Research Report Available Online by Researchmoz.us
7. Global Sealant Industry & China Aerogel Market Size Analysis in New Research Reports at DeepResearchReports.com
8. Commercial Airport Lighting Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
9. PhUSE Working Group Active in Developing Standard Analysis Scripts
10. China Digital Radiography Industry & Global CBCT Market Analysis in a New Research Study Available at DeepResearchReports.com
11. Download Merrill DataSite's Report - Monthly M&A Insider: December 2013 - Analysis of a Mixed M&A Picture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... Yorba Linda, CA (PRWEB) , ... May 23, 2016 , ... ... the task is so routine. A fresh look at this technique may yield ... enhance the reproducibility of experiments in a cell culture laboratory—and lessen the ...
(Date:5/23/2016)... ... , ... NYDNRehab, a New York City-based physical therapy clinic , is ... this type of technology, which was developed by world-renowned researcher Dr. Christopher Powers of ... , With over 10 million sport injuries per year in the United ...
(Date:5/23/2016)... ... ... ComplianceOnline, the leading governance, risk and compliance advisory network with over 1,000 ... and 16, 2016 in San Diego, CA. The two day summit steered by some ... the largest gatherings of medical device companies, suppliers, professionals and experts in 2016. This ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... today that nominations will be accepted May 23, 2016 through August 5, ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:5/23/2016)... ... May 23, 2016 , ... Hadley Institute for the ... who are blind or visually impaired, announces the election of Julie S. Tye ... Young. Hadley’s Board of Trustees retained Morris & Berger, a firm specializing in ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... AVIV, Israel , May 19, 2016 ... or the "Company"), an emerging global ophthalmic company focused ... product candidates which address ophthalmic conditions, announced today that ... Italy ) for the manufacturing, distribution, ... product for the treatment of dry eye syndrome (DES) ...
(Date:5/19/2016)... At the 18 th International Leksell Gamma ... , (May 15-19), Elekta announced that Leksell Gamma ... been used in the treatment of more than one ... functional disorders. Today, Gamma Knife surgery is ... hundreds of leading hospitals and clinics around the world. ...
(Date:5/19/2016)... -- The equities market is never short of ... is without doubt the Healthcare space. ActiveWallSt.com has uncovered four ... Alkermes PLC (NASDAQ: ALKS ), AMAG Pharmaceuticals Inc. ... IDXX ), and Atossa Genetics Inc. (NASDAQ: ... http://www.activewallst.com/ On Wednesday, Alkermes PLC,s ...
Breaking Medicine Technology: